Long-term follow-up of patients treated with Vigabatrin for drug-resistant epilepsy

R. Michelucci, C. A. Tassinari, A. Iudice, J. P. Mumford

Research output: Chapter in Book/Report/Conference proceedingChapter


Twenty-two drug-resistant epileptic pts (21 with complex partial seizures and 1 with Ramsay Hunt syndrome) who had been significantly improved by Vigabatrin during 2 previous controlled trials entered a long-term study with vigabatrin. Five pts were dropped from the study, although 2 of them had a significant seizure frequency decrease. The 17 pts still on Vigabatrin have been followed for a mean period of 20 months (range: 9-33); of them, 13 pts (76%) continue to have a 50% or more decrease in seizure frequency. The remaining 4 pts (24%) feel drug-helped because of a reduction of seizure frequency and intensity. Tolerance to Vigabatrin was good, with the most frequently reported unwanted effect being weight increase. Plasma concentrations of PHT were significantly reduced during long-term treatment. These results demonstrate that the good results obtained with Vigabatrin during the placebo-controlled trials are maintained during the long-term treatment.

Original languageEnglish
Title of host publicationBollettino - Lega Italiana contro l'Epilessia
Number of pages2
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Long-term follow-up of patients treated with Vigabatrin for drug-resistant epilepsy'. Together they form a unique fingerprint.

Cite this